Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.76 USD | -0.56% | +1.15% | -21.78% |
03-21 | Stifel Cuts Price Target on Vor Biopharma to $12 From $15, Maintains Buy Rating | MT |
03-21 | Oppenheimer Cuts Vor Biopharma Price Target to $15 From $18, Maintains Outperform Rating | MT |
Evolution of the average Target Price on Vor Biopharma Inc.
Price target over the last 5 years
History of analyst recommendation changes
Analysts' Consensus
Consensus detail
Consensus revision (last 18 months)
Analysts covering Vor Biopharma Inc.
Oppenheimer | |
Stifel Nicolaus | |
Wedbush | |
JonesTrading Institutional Services | |
Baird | |
HC Wainwright | |
Barclays | |
JMP Securities | |
Goldman Sachs | |
B. Riley | |
Evercore ISI |
EPS Revisions
- Stock Market
- Equities
- VOR Stock
- Consensus Vor Biopharma Inc.